Arcutis Biotherapeutics, Inc.
ARQT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001787306
In the last 90 days, Arcutis Biotherapeutics, Inc. insiders filed 0 open-market purchases and 12 sales; 272 institutions reported holding it in 13F filings for Q2 2026, worth $3.45B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Arcutis Biotherapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 12 filings
- 5 insiders, $2.30M in total
- Insiders trading
- 5
- Net value
- −$2.30M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Arcutis Biotherapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Matsuda Masaru | See Remarks | 112,508 | Sep 18, 2026 | 9 |
| Welgus Howard G. | Director | 35,841 | Sep 17, 2026 | 13 |
| Curran Terrie | Director | 23,526 | Aug 28, 2026 | 3 |
| Burnett Patrick | See Remarks | 117,592 | Aug 21, 2026 | 12 |
| Watanabe Todd Franklin | See Remarks | 717,203 | Aug 5, 2026 | 8 |
| Peetz Christopher | Director | 4,315 | Jul 17, 2026 | 1 |
| Lin Sue-Jean | Director | 27,567 | Jun 17, 2026 | 3 |
| Heron Patrick J | Director | 32,213 | Jun 12, 2026 | 1 |
| Leonard Keith R | Director | 27,901 | Jun 9, 2026 | 3 |
| Gilbert Halley E | Director | 27,901 | Jun 9, 2026 | 2 |
| Munshi Amit | Director | 9,799 | Jun 9, 2026 | 2 |
| Krishnamohan Neha | Director | 27,901 | Jun 9, 2026 | 2 |
| Vairavan Latha | SVP Chief Financial Officer | 85,978 | May 13, 2026 | 5 |
| Edwards Larry Todd | See Remarks | 175,178 | Mar 3, 2026 | 4 |
| Chaudhuri Bhaskar | Director | 867,826 | Jun 16, 2025 | 0 |
| Topper David Joseph | Chief Financial Officer | 182,774 | Apr 3, 2025 | 0 |
| Moore Matthew Richard | SVP and Chief Business Officer | 145,505 | May 3, 2024 | 0 |
| Smither John W | Chief Financial Officer | 11,365 | Feb 15, 2024 | 0 |
| Topper James N | 10% Owner | 8,764,232 | Oct 26, 2023 | 0 |
| Frazier Life Sciences VIII, L.P. | 10% Owner | 8,764,232 | Oct 26, 2023 | 0 |
| FHM Life Sciences VIII, L.P. | 10% Owner | 8,764,232 | Oct 26, 2023 | 0 |
| FHM Life Sciences VIII, L.L.C. | 10% Owner | 8,764,232 | Oct 26, 2023 | 0 |
| Osborne David W | Chief Technical Officer | 268,854 | Mar 8, 2023 | 0 |
| Turney Patricia A. | SVP, Operations | 62,862 | Mar 8, 2023 | 0 |
| Lock Kenneth A. | Chief Commercial Officer | 63,429 | Mar 8, 2023 | 0 |
| Burrows Scott L | Chief Financial Officer | 59,115 | Mar 8, 2023 | 0 |
| OrbiMed Advisors LLC | 10% Owner | 415,142Indirect | Jun 28, 2022 | 0 |
| OrbiMed Capital LLC | 10% Owner | 415,142Indirect | Jun 28, 2022 | 0 |
| OrbiMed Capital GP VII LLC | 10% Owner | 415,142Indirect | Jun 28, 2022 | 0 |
| Turner Joseph L | Director | 4,312 | Jun 3, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 7, 2022 (view filing) | Jan 5 | 2 days | Watanabe Todd FranklinPresident and CEO | SSale | −1.00K | $21.59 | −$21.6K | −0.2%594.8K after | 3 lots |
| Jan 5, 2022 (view filing) | Jan 3 | 2 days | Welgus Howard G.Director | SSale | −2.50K | $21.21 | −$53.0K | −1.4%181.9K after | |
| Dec 28, 2021 (view filing) | Dec 27 | 1 day | Burrows Scott LChief Financial Officer | SSale | −12.6K | $20.07 | −$252.1K | −35.6%22.7K after | |
| Dec 23, 2021 (view filing) | Dec 23 | Same day | Welgus Howard G.Director | SSale | −2.50K | $20.16 | −$50.4K | −1.4%181.9K after | |
| Dec 10, 2021 (view filing) | Dec 8 | 2 days | Watanabe Todd FranklinPresident and CEO | SSale | −1.00K | $17.00 | −$17.0K | −0.2%594.8K after | |
| Nov 9, 2021 (view filing) | Nov 5 | 4 days | Watanabe Todd FranklinPresident and CEO | SSale | −1.00K | $21.50 | −$21.5K | −0.2%594.8K after | |
| Nov 3, 2021 (view filing) | Nov 1 | 2 days | Welgus Howard G.Director | SSale | −2.50K | $21.81 | −$54.5K | −1.4%181.9K after | |
| Oct 7, 2021 (view filing) | Oct 5 | 2 days | Watanabe Todd FranklinPresident and CEO | SSale | −2.50K | $24.92 | −$62.3K | −0.4%594.8K after | |
| Oct 5, 2021 (view filing) | Oct 1 | 4 days | Welgus Howard G.Director | SSale | −2.50K | $23.87 | −$59.7K | −1.4%181.9K after | |
| Oct 5, 2021 (view filing) | Oct 1 | 4 days | Watanabe Todd FranklinPresident and CEO | SSale | −1.50K | $25.01 | −$37.5K | −0.3%594.8K after | |
| Sep 9, 2021 (view filing) | Sep 7 | 2 days | Watanabe Todd FranklinPresident and CEO | SSale | −1.00K | $21.14 | −$21.1K | −0.2%594.8K after | |
| Sep 3, 2021 (view filing) | Sep 1 | 2 days | Welgus Howard G.Director | SSale | −5.00K | $20.80 | −$104.0K | −2.7%181.9K after | 2 lots |
| Aug 9, 2021 (view filing) | Aug 5 | 4 days | Watanabe Todd FranklinPresident and CEO | SSale | −1.00K | $20.81 | −$20.8K | −0.2%594.8K after | |
| Jul 8, 2021 (view filing) | Jul 6 | 2 days | Watanabe Todd FranklinPresident and CEO | SSale | −1.75K | $26.58 | −$46.5K | −0.3%594.8K after | |
| Jul 6, 2021 (view filing) | Jul 1 | 5 days | Welgus Howard G.Director | SSale | −2.20K | $26.13 | −$57.5K | −1.2%181.9K after | 2 lots |